Dendreon Corporation Receives Deloitte & Touche Technology Fast 50 Award for Third Consecutive Year.Business Editors SEATTLE--(BUSINESS WIRE)--Sept. 24, 2003 Dendreon Corporation (Nasdaq:DNDN) today announced that for the third consecutive year, the company has been named one of the 50 fastest growing technology companies in Washington state by Deloitte & Touche as part of its Technology Fast 50 Program. This year, Dendreon received the number 10 ranking in the 2003 Washington State Technology Fast 50 list of companies. "We are pleased to have once again received recognition through the Deloitte & Touche Fast 50 Award program," said Mitchell H. Gold, M.D., chief executive officer of Dendreon. "We are committed to advancing our therapeutic platforms and working to bring new treatment options to cancer patients." The 2003 Washington State Technology Fast 50 ranking is based on an analysis of growth in fiscal year revenues over five years, from 1998 to 2002. The 50 companies who met the Fast 50 eligibility criteria and had the largest percentage revenue increase were included in the list. As a recipient of the Technology Fast 50 Award, Dendreon will be considered for the Deloitte & Touche Technology Fast 500 program, a national ranking of the 500 fastest growing technology companies. Dendreon Corporation is a biotechnology company developing targeted therapies for cancer. The company's lead investigational product candidate, Provenge, is a cancer immunotherapy Cancer immunotherapy is the use of the immune system to reject cancer. The main premise is stimulating the patient's immune system to attack the malignant tumor cells that are responsible for the disease. undergoing a pivotal Phase 3 clinical trial phase 3 clinical trial Phase 3 study. See Phase study. for the treatment of androgen androgen (ăn`drəjən): see testosterone. androgen Any of a group of hormones that mainly influence the development of the male reproductive system. independent prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. . In addition to its immunotherapies in clinical and preclinical preclinical /pre·clin·i·cal/ (-klin´i-k'l) before a disease becomes clinically recognizable. pre·clin·i·cal adj. 1. development for a variety of cancers, Dendreon's product pipeline also includes monoclonal antibody monoclonal antibody, an antibody that is mass produced in the laboratory from a single clone and that recognizes only one antigen. Monoclonal antibodies are typically made by fusing a normally short-lived, antibody-producing B cell (see immunity) to a fast-growing , small molecule and prodrug prodrug /pro·drug/ (-drug) a compound that, on administration, must undergo chemical conversion by metabolic processes before becoming an active pharmacological agent; a precursor of a drug. product candidates. Dendreon has research and development alliances with Genentech, Inc., Kirin Brewery Co., Ltd., Abgenix, Inc. and Dyax Corp. For more information about the company and its programs, visit www.dendreon.com. Except for historical information contained herein, this news release contains forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. that are subject to risks and uncertainties that may cause actual results to differ materially from the results discussed in the forward-looking statements, particularly those risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such a difference include risks related to the uncertainty of Dendreon's future access to capital, including the potential inability to increase revenue growth, Dendreon's limited operating history, risks associated with completing Dendreon's clinical trials, the risk that the safety and/or efficacy results of a clinical trial will not support an application for a biologics license, the risk that the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. will not approve a product for which a biologics license has been applied, the failure by Dendreon to secure and maintain relationships with collaborators, dependence on the efforts of third parties, and dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations, are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion